• Despite challenges, CAR-T may have ‘expanded role' for children

    9 days ago - By Healio

    Chimeric antigen receptor T-cell therapy has been heralded as a transformative addition to the cancer treatment armamentarium.
    Adoption of these therapies for treatment of younger patients, however, has been much less widespread.
    “There are far fewer centers that offer CAR-T for children,” Rebecca A. Gardner, MD, associate professor in the department of pediatrics at University of Washington and attending physician at Seattle Children's Hospital, told Cell Therapy Next.
    The first CAR T-cell therapy approved by the FDA - tisagenlecleucel - was
    Read more ...

     

  • Relapse after CAR-T liked to shorter survival among younger patients with ALL

    9 days ago - By Healio

    Younger patients who experienced disease progression after CD19-directed chimeric antigen receptor T-cell therapy had significantly shorter OS than those who did not relapse, according to results presented at TCT Meetings Digital Experience.
    Results of the retrospective study also showed a lack of a standard approach to salvage therapy for patients who relapse after CAR T-cell therapy, according to Heather E. Stefanski, MD, PhD, associate professor of pediatrics in the division of blood and marrow transplant & cellular therapy at University of Minnesota School of Medicine.
    “We wanted
    Read more ...